iMed.ULisboa Seminar for a Healthy Science – Promoting health by addressing the disease
5 March 2021
Next Friday at 12h, we will have iMed.ULisboa seminars for a Healthy Science dedicated to Emerging technologies and their Impact on health with Prof. Hélder A. Santos
Check the zoom meeting here!
Cloaked Viral Nanovaccines and Exosome‐Based Nanoparticles for Chemo‐immunotherapeutic applications
The recent cutting-edge advances on nanomaterials is anticipated to overcome some of the therapeutic window and clinical applicability of many drug/peptide molecules and can also act as innovative theranostic platform and tool for the clinic in the future [1-4]. In the last decade, research on cancer immunotherapy resulted in a new set of potential treatments with promising results in the clinics [5-8]. Among these, immune checkpoint inhibitors are one of the few immunotherapies that have been clinically validated, yet with variable results, ranging from complete responses to hyperprogression. Amongst the different experimental treatments, active cancer immunotherapy hold great promises for the future. In this work, prominent nanosystems, such as biohybrid nanocomposites made of different nanoparticles (porous silicon and oncolytic virus) and cancer cell-based membrane materials are presented and discussed as potential platforms for the individualization of medical intervention and cancer immunotherapy applications. Examples on how these biohybrid nanomaterials can be prepared and scaled-up, as well as how they can be used to enhance the drug’s targetability, intracellular drug delivery for both cancer chemo- and immune-therapy applications, will be highlighted and discussed. Overall, our results suggest that biohybrid nanomaterials are a versatile and advanced platform for cancer treatment with an interesting potential for present and future clinical impact given its easy tailorability to each patient, choosing a suitable inorganic or virus and obtaining cancer cells from biopsy.
Prof. Santos (D.Sc. Tech., Chem. Eng.) is a Full Professor in Pharmaceutical Nanotechnology, Head of the Nanomedicines and Biomedical Engineering Group, and Director of the Doctoral Program in Drug Research at the Faculty of Pharmacy, at the University of Helsinki. He is also a Fellow Member of Helsinki Institute of Life Science (HiLIFE), the Director of the FinPharmaNet (The Network of Drug Research Doctoral Programmes in Finland), Chair of Controlled Release Society Focus Group in Nanomedicine and Nanoscale Delivery, and Chairman and co-founder of Capsamedix Oy. Prof. Santos research interests include the development of nanoparticles/nanomedicines for biomedical applications. Prof. Santos is co-author of more than 350 publications (+11000 citations; h-index = 62), and more than 275 conference proceedings/abstracts. He has given over 175 invited talks at prestigious conferences, universities and schools around the world. Prof. Santos has received a number of prestigious awards and grants, such as the “Talent Prize in Science” attributed by the Portuguese Government in 2010, the European Research Council (ERC) Starting Grant (1.5 M€) in 2013 and ERC Proof-of-Concept in 2018, the Young Researcher Award in 2013 attributed by the Faculty of Pharmacy of the University of Helsinki, the Academy of Finland Award for Social Impact in 2016, and is currently the coordinator of H2020 MSCA-ITN-EJD network (~4.1 M€).